Solid Biosciences (SLDB) CTO gets options, RSUs and sells shares

Rhea-AI Filing Summary

Solid Biosciences Chief Technology Officer Paul Herzich reported several equity award events and a related share sale. On January 29, 2026, 54,925 performance stock units vested and converted one-for-one into common stock after a performance milestone was certified as achieved.

On the same date, he received an option to buy 170,000 shares at an exercise price of $6.60 per share, vesting over four years, and was granted 85,000 restricted stock units, also vesting over four years. On January 31, 2026, 24,675 RSUs from a 2025 grant vested and converted into common shares.

On February 2, 2026, Herzich sold 26,250 common shares at a weighted average price of $6.4369 per share to cover withholding taxes after PSU vesting, under a durable automatic sell-to-cover instruction, and not as a discretionary trade. After these transactions, he directly owned 79,972 common shares.

Insider Trade Summary

Net Seller: 26,250 shares ($168,969)

Net Sell 7 txns

Insider Herzich Paul

Role Chief Technology Officer

Sold 26,250 shs ($169K)

Type	Security	Shares	Price	Value
Sale	Common Stock	26,250	$6.4369	$169K
Exercise	Restricted Stock Units	24,675	$0.00	--
Exercise	Common Stock	24,675	$0.00	--
Exercise	Performance Stock Units	54,925	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	170,000	$0.00	--
Grant/Award	Restricted Stock Units	85,000	$0.00	--
Exercise	Common Stock	54,925	$0.00	--

Holdings After Transaction: Common Stock — 79,972 shares (Direct); Restricted Stock Units — 74,025 shares (Direct); Performance Stock Units — 0 shares (Direct); Employee Stock Option (Right to Buy) — 170,000 shares (Direct)

Footnotes (1)

1. Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis. Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 98,700 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Herzich Paul

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/29/2026		M		54,925	A	(1)	81,547	D
Common Stock	01/31/2026		M		24,675	A	(2)	106,222	D
Common Stock	02/02/2026		S		26,250(3)	D	$6.4369(4)	79,972	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	01/29/2026		M			54,925	(5)	(5)	Common Stock	54,925	$0.00	0	D
Employee Stock Option (Right to Buy)	$6.6	01/29/2026		A		170,000		(6)	01/29/2036	Common Stock	170,000	$0.00	170,000	D
Restricted Stock Units	(2)	01/29/2026		A		85,000		(7)	(7)	Common Stock	85,000	$0.00	85,000	D
Restricted Stock Units	(2)	01/31/2026		M			24,675	(8)	(8)	Common Stock	24,675	$0.00	74,025	D

Explanation of Responses:

1. Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.

2. Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.

3. This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

5. The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.

6. This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.

7. The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.

8. On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 98,700 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.

	/s/ Kimberly Cornwell as attorney-in-fact for Paul Herzich	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Solid Biosciences (SLDB) disclose for CTO Paul Herzich?

The filing shows PSU and RSU vesting, new option and RSU grants, and a tax-related share sale. PSUs and RSUs converted into common stock, while a 170,000-share option and 85,000 RSUs were granted with multi-year vesting schedules.

How many Solid Biosciences shares did CTO Paul Herzich sell and at what price?

He sold 26,250 shares of Solid Biosciences common stock at a weighted average price of $6.4369 per share. The sale occurred on February 2, 2026 and was executed in multiple trades within a disclosed price range.

Why did Solid Biosciences CTO Paul Herzich sell 26,250 SLDB shares?

The sale was made solely to cover withholding taxes after previously granted performance stock units vested. It was executed under a durable automatic sell-to-cover instruction adopted in August 2024, and the company states it was not a discretionary trade by Herzich.

What new stock options did the Solid Biosciences CTO receive?

On January 29, 2026, Herzich received an employee stock option covering 170,000 shares with a $6.60 exercise price. The option vests over four years, with 25% after one year and the remainder vesting monthly until the fourth anniversary.

What restricted stock units were granted to Solid Biosciences CTO Paul Herzich?

He was granted 85,000 new restricted stock units on January 29, 2026, vesting in four equal annual installments. Additionally, 24,675 RSUs from a January 31, 2025 grant vested on January 31, 2026 and converted into the same number of common shares.

How many Solid Biosciences shares did the CTO own after these Form 4 transactions?

After the reported transactions, Herzich directly owned 79,972 shares of Solid Biosciences common stock. He also held derivative awards, including 170,000 stock options and 74,025 restricted stock units that remain outstanding and subject to future vesting.